Alexander Straub serves as a Head of Medicinal Chemistry for FundaMental Pharma.

He is an accomplished drug hunter and inventor of the Factor Xa inhibitor blockbuster rivaroxaban (Xarelto(R)) and of the sGC stimulator riociguat (Adempas (R)), both from Bayer AG.

He began his career in 1989 with Bayer AG in Wuppertal as a medicinal chemist, working in drug discovery programmes with a cardiovascular focus.

In 2000, he moved to the Bayer CropScience division, working in process research on several developmental products in Monheim, and then moved to Dormagen as a process development chemist. From 2008 to 2019, he has been a Principal Research Scientist at Bayer AG, Pharma, Wuppertal, working in cardiovascular indications.

Alexander Straub holds a German Diploma (MSc) and PhD from the University of Stuttgart, Germany. He has co-authored over 50 publications and >60 patent applications.